Cardiac Mapping Devices Market Size, Share & Trends Analysis Report, By Type (Contact Cardiac Mapping Systems, Non-Contact Cardiac Mapping Systems), By Indication (Atrial Fibrillation, Atrial Flutter), By End Use, By Region, And Segment Forecasts, 2024 -

Cardiac Mapping Devices Market Size, Share & Trends Analysis Report, By Type (Contact Cardiac Mapping Systems, Non-Contact Cardiac Mapping Systems), By Indication (Atrial Fibrillation, Atrial Flutter), By End Use, By Region, And Segment Forecasts, 2024 - 2030

Cardiac Mapping Devices Market Growth & Trends

The global cardiac mapping devices market size is expected to reach USD 3.69 billion by 2030, registering a CAGR of 9.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary factors driving the market expansion include the rising arrhythmia cases & number of cardiac surgery patients, growing geriatric population, technological advancements in cardiac mapping systems, and supportive government initiatives. According to the Heart Rhythm Society article published in August 2023, Atrial fibrillation (AFib), the most common type of cardiac arrhythmia, affects nearly 40 million people worldwide, including 6 million in the U.S. Its widespread prevalence underscores the need for advanced diagnostic and treatment options.

Approximately 1 in 4 adults over 40 are at risk of developing AFib, yet many are unaware of its symptoms, available treatments, and the importance of early intervention to prevent progression. Advancements in cardiac mapping systems also drive market growth. For instance, in June 2024, new mapping techniques, such as multielectrode baskets and catheters mapping across cardiac arteries and veins on the epicardium, enabled three-dimensional activation sequence definition during vacuum therapy. Computerized non-contact mapping uses mathematical algorithms to reconstruct electrograms and generate three-dimensional isopotential maps without direct heart endocardium contact.

Advances in remote monitoring and infection prevention in cardiac electrophysiology support continuous patient heart rhythm monitoring outside clinical settings, allowing prompt treatment adjustments and reducing invasive procedure infection risks. Moreover, several strategic initiatives by key players fuel the market’s growth. For instance, in July 2024, Johnson & Johnson’s Biosense Webster launched the Optrell mapping catheter, incorporating TrueRef technology. Designed in Irvine, California, by Biosense Webster, Optrell is a high-density diagnostic catheter that integrates with the Carto 3 system. It utilizes small electrodes in a fixed array configuration to provide accurate electrophysiological mapping for complex cardiac arrhythmias.

Cardiac Mapping Devices Market Report Highlights

• The contact cardiac mapping systems segment held the largest share of over 57.07%, in 2023 due to technological advancements, strategic initiatives by key players, and a rising volume of cardiac procedures
• The atrial fibrillation segment held the largest share of over 45.87% in 2023 due to increased cases of arrhythmia and high geriatric population
• The hospitals segment held the largest share of 69.38% in 2023. Hospitals play a vital role in adopting and assessing new technologies, such as advanced cardiac mapping devices. These devices enable hospitals to deliver state-of-the-art care for patients with cardiac arrhythmias, ensuring better outcomes and advancing the field of electrophysiology
• North America dominated the global market with a share of 41.39% in 2023 owing to the increased cases of cardiovascular diseases (CVDs), including arrhythmias. Product launches, regulatory approvals, and advanced healthcare infrastructure

Please note The report will be delivered in 2-3 business days upon order notification.